...
首页> 外文期刊>Seminars in Respiratory and Critical Care Medicine >Management of the patient with a malignant pleural effusion.
【24h】

Management of the patient with a malignant pleural effusion.

机译:恶性胸腔积液患者的处理。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A malignant pleural effusion (MPE) establishes an incurable stage of a malignancy. Median survival after detection of an MPE is 4 to 6 months in general populations of patients with cancer. Management of MPE centers on palliation of symptoms because no available treatments prolong survival. Mismanagement of MPE, however, can shorten survival and add to patients' burden of disease. Appropriate management requires a multidisciplinary approach with competency in existing treatment modalities to allow individualization of care. Although few prospective studies exist to guide clinical decisions, treating centers should present to patients the relative risks and benefits of different approaches and ensure that their institution's clinical outcomes in managing MPE match those of best clinical practices reported in the literature. Treatment of MPE is moving toward less interventional approaches that can manage patients in ambulatory settings thereby decreasing cost, discomfort, and time away from home for inpatient care.
机译:恶性胸腔积液(MPE)建立了恶性肿瘤的无法治愈的阶段。在患有癌症的普通人群中,检测到MPE后的中位生存期为4到6个月。 MPE的管理集中在症状减轻上,因为没有可用的治疗方法可以延长生存期。但是,MPE管理不当会缩短生存期并增加患者的疾病负担。适当的管理需要采用多学科方法,并具有在现有治疗方式中的能力,以使护理个性化。尽管很少有前瞻性研究指导临床决策,但治疗中心应向患者介绍不同方法的相对风险和益处,并确保其机构在管理MPE方面的临床结果与文献报道的最佳临床实践相符。 MPE的治疗正朝着更少介入的方法发展,该方法可在非卧床环境中管理患者,从而降低成本,不适感和出门在外的住院时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号